Recent Advances in the Development of Nanodelivery Systems Targeting the TRAIL Death Receptor Pathway

• Published in: Pharmaceutics 2023-02, Vol.15 (2), p.515
• Main Authors: Yagolovich, Anne V, Gasparian, Marine E, Dolgikh, Dmitry A
• Format: Article
• Language: English
• Subjects: Antimitotic agents; Antineoplastic agents; Apoptosis; Biocompatibility; Breast cancer; Cancer therapies; death receptors; Dosage and administration; DR5; drug delivery; Drug delivery systems; Drugs; FDA approval; Gold; Health aspects; Hyperthermia; Innovations; ligand-targeted drugs; Ligands; Medical research; Metastasis; Nanomaterials; Nanomedicine; Nanoparticles; Peptides; Proteins; receptor clustering; Review; Silver; Toxicity; TRAIL; Tumor necrosis factor; Tumor necrosis factor-TNF; Vehicles
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics15020515

The TRAIL (TNF-related apoptosis-inducing ligand) apoptotic pathway is extensively exploited in the development of targeted antitumor therapy due to TRAIL specificity towards its cognate receptors, namely death receptors DR4 and DR5. Although therapies targeting the TRAIL pathway have encountered many obstacles in attempts at clinical implementation for cancer treatment, the unique features of the TRAIL signaling pathway continue to attract the attention of researchers. Special attention is paid to the design of novel nanoscaled delivery systems, primarily aimed at increasing the valency of the ligand for improved death receptor clustering that enhances apoptotic signaling. Optionally, complex nanoformulations can allow the encapsulation of several therapeutic molecules for a combined synergistic effect, for example, chemotherapeutic agents or photosensitizers. Scaffolds for the developed nanodelivery systems are fabricated by a wide range of conventional clinically approved materials and innovative ones, including metals, carbon, lipids, polymers, nanogels, protein nanocages, virus-based nanoparticles, dendrimers, DNA origami nanostructures, and their complex combinations. Most nanotherapeutics targeting the TRAIL pathway are aimed at tumor therapy and theranostics. However, given the wide spectrum of action of TRAIL due to its natural role in immune system homeostasis, other therapeutic areas are also involved, such as liver fibrosis, rheumatoid arthritis, Alzheimer's disease, and inflammatory diseases caused by bacterial infections. This review summarizes the recent innovative developments in the design of nanodelivery systems modified with TRAIL pathway-targeting ligands.